Aurobindo Pharma AUROPHARMA
Largest Indian exporter of generics to the US by volume, with Eugia injectables, Europe, APIs and a Pen-G KSM project
Mapped in 1 theme: Pharmaceuticals.
Where Aurobindo Pharma sits in the supply chain
Aurobindo Pharma appears in 4 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Pharmaceuticals › Sterile injectables & fill-finish
Direct supplierOther companies in this layer
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Pharmaceuticals › KSMs & intermediates
Emerging entrantOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 29,002 | 31,724 | 33,653 |
| Net profit | 3,169 | 3,484 | 3,503 |
Latest-year revenue ₹33,653 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Huge US portfolio and among the deepest ANDA pipelines - low dependence on any single product
- Backward integrated from KSMs (Pen-G/6-APA plant under PLI) to APIs to formulations
- CuraTeQ biosimilars and European business diversify earnings
Risks
- Eugia sterile sites under USFDA action: Unit III WL (2024), Unit II OAI (Mar 2026), Unit I WL (Aug 2026, ~2% of revenue)
- High US exposure (~45% of sales) to price erosion and the 2028 tariff clock
- Low ROE versus peers
Common questions
What does Aurobindo Pharma do?
Largest Indian exporter of generics to the US by volume, with Eugia injectables, Europe, APIs and a Pen-G KSM project.
Where does Aurobindo Pharma sit in the supply chain?
Aurobindo Pharma (NSE: AUROPHARMA) is mapped in 4 supply-chain layers: Generics (US & export) (Pharmaceuticals), Sterile injectables & fill-finish (Pharmaceuticals), APIs (active ingredients) (Pharmaceuticals) and KSMs & intermediates (Pharmaceuticals).
Who are Aurobindo Pharma's peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Lupin, Zydus Lifesciences, Cipla, Sun Pharmaceutical Industries, Alembic Pharmaceuticals and 6 more.
What is Aurobindo Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹97,030 Cr, P/E 25.7x, ROCE 12.9%, ROE 10.1%, dividend yield 0.24%.